Global TROP2 Antibody Market Report 2021-2026: Opportunity Assessment, Drug Sales, Approved Drugs, Patent, Price and Sales, Competitor Landscape – Yahoo Finance

Science & Technology

DUBLIN, Dec. 20, 2021 /PRNewswire/ — The "Global TROP2 Antibody Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
The global Trop2 targeting drug market is expected to surpass US$ 4 Billion by 2026
Surge in prevalence of cancer across geographies, high demand for targeted therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers, and rise in awareness of Trop-2 targeting drug owing o high efficiency will propel the growth of market.
In addition, surge in geriatric population and increase in technological advancements in screening & diagnosis of cancer supplement the market growth.
The key players in the TROP2 Antibody market include Daiichi Sankyo, Immunomedics, Gilead Sciences, AstraZeneca, Pfizer, BioThera Solution, and others. The major players in the market have adopted strategic alliances such as collaboration, partnerships, or joint ventures to cope up with the high cost of research and development and to maintain their share in market.
For instance, Daiichi Sankyo and AstraZeneca have recently announced second trial collaboration with Merck to evaluate the combination of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) and Keytruda in non-small cell lung cancer patients.
Studies have also demonstrated that Trop2 is highly expressed on several cancer cells and is generally associated with its aggressive nature. Apart from this, it is also involved in several signaling pathways which ultimately lead to cancer cell growth and proliferation. Therefore, targeting Trop2 can be an alternative to target cancer.
Recently, scientists developed novel antibody drug conjugate in which the therapeutic antibody is targeted towards Trop2, thereby delivering the cytotoxin to the surface of tumor cell. Sacituzumab govitecan-hziy (Trodelvy) developed by Immunomedics is the first trop2 targeted antibody drug conjugate which has been approved for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
The introduction of Trodelvy in 2020 is expected to witness high growth rates in market due to lack of effective targeted therapies in mTNBC. It is believed that Trodelvy will revolutionize the overall treatment of TNBC and will significantly improve the survival outcomes.
Beyond the approval of Trodelvy in US, it has also gained approval in Australia, Canada, UK, and Switzerland for adults with metastatic TNBC. Apart from this, the drug is present in regulatory view in other regions including Europe, China and Singapore.
Recently, European Medicines Agency has recommended the marketing of Trodelvy, indicating that the drug will enter the market in coming months. The rapid approval of drug in different regions will fuel the growth of market in coming years.
The quick approval of Trodelvy has further empowered innovation and development in this sector. To date, a cocktail of Trop2 targeted drugs including DS-1062a, RN927C, BAT8003, SKB264, JS108 are present in clinical development.
These drugs have been designed to target a wide range of cancer including non-small cell lung cancer, epithelial cancer, skin cancer, colon cancer, and others.
Apart from this, several investigational studies are also ongoing to evaluate the efficacy of Trodelvy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. The forthcoming years will see rapid influx of Trop-2 targeted therapies in wide range of cancers.
Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:

Research Methodology
Global & Regional Market Analysis
Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion
Market and Drug Sales Insight 2020 Till 2026
Approved Drug In Market: 1 Drugs
Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026
Future Market Assessment By Indication Till 2026
Ongoing Clinical Trials Assessment by Status, Phase & Region
Key Market Dynamics
Competitor Landscape
Key Topics Covered:
1. Introduction to TROP2 Targeting Therapy Market
1.1 Overview
1.2 History of TROP2 Targeting Therapeutics
2. TROP2 Ideal Clinical Biomarker for Cancer
3. TROP2 Targeting Therapeutics Mechanism
4. Global TROP2 Targeting Therapy Market Analysis
4.1 Current Market Scenario
4.2 Future Market Opportunity
5. Global TROP2 Targeting Therapy Market Opportunity by Region
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World
6. Global TROP2 Targeting Therapy Market by Cancer
6.1 Breast Cancer
6.2 Urothelial Carcinoma
6.3 Lung Cancer
6.4 Pancreatic Cancer
6.5 Prostate Cancer
7. First Approved TRO2 Targeting Antibody – Trodelvy (Sacituzumab Govitecan)
7.1 Overview
7.2 Approval, Patent & Exclusivity
8. Trodelvy – Commercial Information
8.1 Dosage & Price Analysis
8.2 Sales Analysis
9. Trodelvy Sales Forecast 2026
10. TROP2 Targeted Therapy Clinical Trials Insight
10.1 By Phase
10.2 By Development Status
10.3 By Region
11. Global TROP2 Targeting Therapy Market – Ongoing Research & Development
11.1 Datopotamab Deruxtecan (DS-1062)
11.2 SKB264
11.3 JS108
11.4 BAT 8003
11.5 Trodelvy (Sacituzumab Govitecan)
12. Global TROP2 Targeted Therapy Market Dynamics
12.1 Market Drivers
12.2 Market Challenges
13. Global TROP2 Targeting Therapy Market Future Outlook
14. Competitive Landscape
14.1 Amunix
14.2 ARIUS Research
14.3 AstraZeneca
14.4 Biothera
14.5 Daiichi Sankyo Company
14.6 Gilead
14.7 Immunomedics
14.8 Janux Therapy
14.9 Klus Pharma
14.10 Myeloid therapeutics
14.11 Pfizer Inc
14.12 Shanghai Junshi Bioscience
For more information about this report visit https://www.researchandmarkets.com/r/c3wxuv
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/global-trop2-antibody-market-report-2021-2026-opportunity-assessment-drug-sales-approved-drugs-patent-price-and-sales-competitor-landscape-301448417.html
SOURCE Research and Markets
While there's no way to know for sure if a given stock has what it takes to outperform, looking at a company's upcoming catalysts is one trick that can help to stack the deck in your favor. Catalyst Pharmaceuticals (NASDAQ: CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%.
Novavax’s vaccine has been recommended for use by the European Medicines Agency, marking the first endorsement by a major regulator of a shot that uses an established vaccine technology.
The FDA has approved Intra-Cellular Therapies Inc (NASDAQ: ITCI) Caplyta for depressive episodes associated with bipolar I or II disorder in adults. The approval for Caplyta comes as monotherapy and as adjunctive therapy with lithium or valproate. The drug has shown a favorable profile on weight, cardiometabolic parameters, and extrapyramidal symptoms (movement disturbances). Related content: Benzinga's Full FDA Calendar. The Company says it is positioned to launch the drug immediately. The appr
As cases of the Omicron variant spread, it's important to know the CDC's new standards for face masks. Here's how to check your mask using the new CDC guidelines.
As coronavirus cases surge across the nation at an unrelenting pace, experts are predicting a "blizzard" or "tsunami" of COVID to sweep the nation. "This Omicron variant is extraordinarily contagious. It's as contagious as measles, and that's about the most contagious virus that we've seen," CNN medical analyst Jonathan Reiner told CNN's Pamela Brown Saturday. How can you stay safe? Dr. Anthony Fauci, the chief medical advisor to the President and the director of the National Institute of Allerg
The two-dose protein-based vaccine, branded Nuvaxovid, is the fifth coronavirus vaccine recommended by the EU.
(Bloomberg) — Daily infections in South Africa, where the omicron variant was first identified, almost halved, though hospital admissions and deaths rose significantly. Singapore expects more cases after discovering its first suspected local omicron cluster.Most Read from BloombergModerna’s Third Dose Boosts Antibodies Against OmicronS&P 500 Has Biggest Three-Day Drop Since September: Markets WrapBilly Joel NYC Show Going Ahead; Quebec Closures: Virus UpdateOmicron Becomes Dominant U.S. Strain
Bitcoin closed out Monday in positive territory. The upside amidst a global equity sell-off that saw the Dow give up 433 points on the day.
Biogen Inc.'s decision to cut the price of its Alzheimer's drug Aduhelm in half starting Jan. 1 is "a day late and a dollar short," according to Raymond James, which is not expecting the move to change the trajectory of the drug launch or restore Biogen's battered reputation.
The company just revealed disappointing phase 3 trial results for its only clinical-stage drug candidate.
Working conditions are deteriorating at big chain pharmacies including CVS, Walgreens and Rite Aid, which are central to the country’s pandemic testing and vaccination efforts, according to dozens of employees, organizations representing pharmacists and experts in the field.
A recent study that surveyed average retirees between age 62 and 75 and found that three-quarters of them had seen their assets remain the same or grow in retirement.
Biogen slashed the price of its controversial Alzheimer's drug, Aduhelm, on Monday amid a lukewarm launch — but Biogen stock sank.
When looking for the best artificial intelligence stocks to buy, identify companies using AI technology to improve products or gain a strategic edge, such as Google, Microsoft and Nvidia.
You know how to stay healthy after 50, right? Eat less processed food, move more, et cetera. Well, yes. But the reality is, maintaining optimum health in middle age and beyond is a bit more complicated—experts say you should avoid lapsing into some common (but often overlooked) bad habits. These are five things you should never do after age 50. Read on—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 Don't Skip Routine Screenings Your 50
It might be time to step up from cloth if you're in an area with high transmission.
The commissioner of the Kentucky Department for Public Health calls the newest variant of COVID-19 "probably one of the most transmissible or contagious infections we've had in the past century."
Texas Oncology now has 2 surgeons who can do treatment that washes abdomen with heated chemotherapy after as much cancer as possible is scraped out.
General Mills is expected to report their latest quarterly figures Tuesday morning. I am done with breakfast so let's take a couple of minutes to check on the charts. In this daily bar chart of GIS, below, we can see that this month prices broke out over the highs of May and June.
Does anyone doubt that planning for retirement is unique for each individual? The way we manage money, how we handle debt, our desired lifestyle and our family status are all important variables to consider. Now, he’s turned his lifestyle into a lucrative video business.

source